EGLN3 and neoplasm: Unlike most of the studies targeting FIH describing a commonly reduced expression in tumor [44–46], clinical investigations on PHD3 had controversial results, such as elevated in pancreaticobiliary cancer and HNSCC [39, 47] but reduced in gastric cancer [48].